Lynparza Approval History
- FDA approved: Yes (First approved December 19th, 2014)
- Brand name: Lynparza
- Generic name: olaparib
- Dosage form: Capsules
- Company: AstraZeneca Pharmaceuticals LP
- Treatment for: Ovarian Cancer
Lynparza (olaparib) is a first-in-class oral poly ADP ribose polymerase (PARP) inhibitor for the treatment of advanced ovarian cancer.
Development History and FDA Approval Process for Lynparza
|Dec 19, 2014||FDA Approves Lynparza (olaparib) to Treat Advanced Ovarian Cancer|
|Jun 25, 2014||FDA Advisory Committee Votes on Accelerated Approval for Investigational Medicine Olaparib|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.